Publication | Open Access
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
60
Citations
33
References
2013
Year
The addition of bevacizumab to FOLFOXIRI produces high rates of pathologic responses and necrosis of CLM without increasing liver toxicity.
| Year | Citations | |
|---|---|---|
Page 1
Page 1